

Nikolaus D Schultz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2457490/nikolaus-d-schultz-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

237
papers

94,864
citations

105
h-index

256
g-index

256
ext. papers

122,579
ext. citations

17.7
avg, IF

8.88
L-index

#	Paper	IF	Citations
237	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102029	2.2	3
236	Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100401	3.6	
235	Genome Nexus: A Comprehensive Resource for the Annotation and Interpretation of Genomic Variants in Cancer.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100144	5.2	0
234	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11	56.2	11
233	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100242	3.6	0
232	MITI minimum information guidelines for highly multiplexed tissue images.. <i>Nature Methods</i> , 2022 , 19, 262-267	21.6	2
231	The context-specific role of germline pathogenicity in tumorigenesis. <i>Nature Genetics</i> , 2021 , 53, 1577-1585	35.3	6
230	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. <i>Nature Communications</i> , 2021 , 12, 6821	17.4	2
229	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2021 ,	12.9	6
228	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 221-230	5.2	11
227	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021 , 160, 696-703	4.9	0
226	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. <i>Clinical Cancer Research</i> , 2021 , 27, 3491-3498	12.9	1
225	The genomic landscape of carcinomas with mucinous differentiation. <i>Scientific Reports</i> , 2021 , 11, 9478	4.9	1
224	A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles.. <i>Cell Reports Methods</i> , 2021 , 1, 100039		1
223	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
222	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2114753	10.4	4
221	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 5595-5606	12.9	3

220	Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin. <i>Annals of Surgical Oncology</i> , 2021 , 28, 1109-1117	3.1	1
219	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021 , 2, 357-365	15.4	23
218	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021 , 156, e205601	5.4	16
217	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2117547	10.4	2
216	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	12
215	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2698-2709	2.2	16
214	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021 , 74, 1429-1444	11.2	14
213	Patterns of Metastatic Disease in Patients with Cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-year Period. <i>Radiology</i> , 2021 , 301, 115-122	20.5	4
212	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021 , 27, 2226-2235	12.9	6
211	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2020 , 21, 821-831	21.7	104
210	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3230-3238	12.9	49
209	Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. <i>Molecular Oncology</i> , 2020 , 14, 1881-1897	7.9	5
208	Phase and context shape the function of composite oncogenic mutations. <i>Nature</i> , 2020 , 582, 100-103	50.4	13
207	Recent Advances in Systems and Network Medicine: Meeting Report from the First International Conference in Systems and Network Medicine. <i>Systems Medicine (New Rochelle, N Y)</i> , 2020 , 3, 22-35	1.6	4
206	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 3271-3279	12.9	41
205	A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. <i>Nature Genetics</i> , 2020 , 52, 448-457	36.3	58
204	Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e151-e156	3.8	4
203	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020 , 25, e68-e74	5.7	5

202	Characteristics and Outcome of -Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020 , 10, 526-535	24.4	19
201	Coaltered and Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1077-1085	12.9	37
200	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. <i>European Urology</i> , 2020 , 78, 671-679	10.2	37
199	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020 , 26, 3239-3247	12.9	58
198	Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy. <i>Annals of Surgery</i> , 2020 ,	7.8	4
197	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020 , 6, 84-91	13.4	33
196	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 60-67	13.4	55
195	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	6
194	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020 , 1, 1041-1053	15.4	18
193	Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer. <i>Gastroenterology</i> , 2020 , 159, 1975-1978.e4	13.3	4
192	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1844-1856	8.9	20
191	Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling. <i>JCO Clinical Cancer Informatics</i> , 2020 , 4, 691-699	5.2	1
190	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. <i>JCO Precision Oncology</i> , 2020 , 4, 355-366	3.6	35
189	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 7475-7484	12.9	14
188	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 11428-11436	11.5	383
187	The expanding landscape of SncohistoneSmutations in human cancers. <i>Nature</i> , 2019 , 567, 473-478	50.4	151
186	Efficacy of Combined VEGFR1-3, PDGFR and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3811-3817	12.9	5
185	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with -Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 1063-1069	12.9	156

184	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 355-362	7.6	9
183	Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis. <i>Nature Communications</i> , 2019 , 10, 3682	17.4	23
182	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6160-6169	12.9	45
181	Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019 , 571, 576-579	50.4	170
180	Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 1893-1898	7.6	50
179	Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019 , 8, 6538-6548	4.8	5
178	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4276-4289	15.9	64
177	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019 , 8,	8.9	17
176	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. <i>Blood</i> , 2019 , 134, 2148-2148	2.2	0
175	Data Portals and Analysis 2019 , 169-196		1
174	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
173	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	27
172	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. <i>JAMA Oncology</i> , 2019 , 5, 471-478	13.4	257
171	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019 , 9, 199-209	24.4	79
170	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. <i>Molecular Cancer Research</i> , 2019 , 17, 446-456	6.6	22
169	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019 , 25, 2116-2126	12.9	219
168	FOLFDCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e39-e52	3.8	9
167	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019 , 75, 231-239	10.2	53

166	The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. <i>Cancer Cell</i> , 2018 , 33, 527-541.e855	54.3	855
165	Unifying cancer and normal RNA sequencing data from different sources. <i>Scientific Data</i> , 2018 , 5, 180068.2	6.2	66
164	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018 , 173, 400-416.e11	56.2	1072
163	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018 , 173, 371-385.e18	56.2	854
162	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018 , 173, 291-304.e6	56.2	888
161	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , 2018 , 173, 386-399.e342	56.2	133
160	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018 , 173, 305-320.e10	56.2	166
159	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018 , 173, 338-354.e15	56.2	560
158	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018 , 173, 321-337.e10	56.2	1124
157	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , 2018 , 173, 355-370.e14	56.2	342
156	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , 2018 , 23, 282-296.e4	10.6	188
155	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018 , 23, 227-238.e3	10.6	235
154	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018 , 23, 313-326.e5	10.6	295
153	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , 2018 , 23, 181-193.e7	10.6	366
152	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
151	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 172-180.e3	10.6	66
150	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018 , 23, 239-254.e6	10.6	405
149	G2S: a web-service for annotating genomic variants on 3D protein structures. <i>Bioinformatics</i> , 2018 , 34, 1949-1950	7.2	7

148	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018 , 8, 174-183	24.4	162
147	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 33, 125-136.e3	24.3	338
146	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , 2018 , 6, 282-300.e2	10.6	159
145	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , 2018 , 33, 706-720.e9	24.3	275
144	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018 , 33, 676-689.e3	24.3	377
143	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018 , 33, 721-735.e8	24.3	228
142	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
141	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 645-651	36.3	380
140	Systematic Functional Annotation of Somatic Mutations in Cancer. <i>Cancer Cell</i> , 2018 , 33, 450-462.e10	24.3	114
139	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018 , 34, 211-224.e6	24.3	327
138	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018 , 50, 1189-1195	36.3	208
137	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2027-2033	3.1	12
136	Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2018 , 24, 6556-6569	12.9	44
135	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018 , 23, 3392-3406.e10	10.6	200
134	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. <i>ELife</i> , 2018 , 7,	8.9	114
133	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018 , 24, 1965-1973	12.9	51
132	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018 , 8, 49-58	24.4	180
131	American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions Perspectives. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-14	5.2	13

130	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018 , 36, 633-641	2.2	730
129	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4441-4453	15.9	84
128	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018 , 34, 893-905.e8	24.3	166
127	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
126	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018 , 34, 427-438.e6	24.6	339
125	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018 , 24, 4154-4161	12.9	182
124	KMT2C mediates the estrogen dependence of breast cancer through regulation of ER α enhancer function. <i>Oncogene</i> , 2018 , 37, 4692-4710	9.2	48
123	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. <i>Genome Medicine</i> , 2017 , 9, 4	14.4	117
122	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2017 , 77, 1035-1046	10.1	12
121	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , 2017 , 13, 914	12.2	44
120	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017 , 23, 703-713	50.5	1638
119	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017 , 19, 1380-1390	1390	20
118	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , 2017 , 169, 1327-1341.e23	56.2	1125
117	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017 , 7, 1018-1029	24.4	201
116	ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. <i>Nature</i> , 2017 , 546, 671-675	675	47
115	PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data. <i>Bioinformatics</i> , 2017 , 33, 2238-2240	7.2	31
114	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017 , 7, 596-609	24.4	317
113	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017 , 30, 599-609	9.8	43

112	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017 , 171, 540-556.e25	9.5	961
111	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017 , 72, 952-959	10.2	168
110	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	151
109	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	699
108	The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing. <i>Science Signaling</i> , 2017 , 10,	8.8	33
107	Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies. <i>Cancer Cell</i> , 2017 , 32, 155-168.e6	24.3	61
106	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017 , 23, 6094-6100	12.9	107
105	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017 , 171, 950-965.e28	56.2	451
104	Mitochondrial respiratory gene expression is suppressed in many cancers. <i>ELife</i> , 2017 , 6,	8.9	64
103	Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. <i>Clinical Cancer Research</i> , 2016 , 22, 971-83	12.9	70
102	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016 , 7, 13131	17.4	90
101	MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer. <i>Nucleic Acids Research</i> , 2016 , 44, D986-91	20.1	11
100	rCellMiner: exploring molecular profiles and drug response of the NCI-60 cell lines in R. <i>Bioinformatics</i> , 2016 , 32, 1272-4	7.2	30
99	Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. <i>Nature</i> , 2016 , 531, 471-475	50.4	142
98	Translational Bioinformatics and Clinical Research (Biomedical) Informatics. <i>Clinics in Laboratory Medicine</i> , 2016 , 36, 153-81	2.1	4
97	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016 , 22, 369-78	50.5	425
96	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. <i>Nature Biotechnology</i> , 2016 , 34, 155-63	44.5	465
95	Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. <i>JCI Insight</i> , 2016 , 1,	9.9	32

94	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1052-66	15.9	576
93	A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers. <i>PLoS Computational Biology</i> , 2016 , 12, e1004765	5	23
92	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
91	The metabolic co-regulator PGC1 β suppresses prostate cancer metastasis. <i>Nature Cell Biology</i> , 2016 , 18, 645-656	23.4	140
90	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016 , 151, 278-287.e6	13.3	109
89	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4623-33	12.9	114
88	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016 , 29, 723-736	24.3	324
87	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4000-4007	2.2	110
86	Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. <i>Cancer Discovery</i> , 2015 , 5, 842-9	24.4	409
85	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015 , 372, 2481-98	59.2	1828
84	Translational Bioinformatics and Clinical Research (Biomedical) Informatics. <i>Surgical Pathology Clinics</i> , 2015 , 8, 269-88	3.9	5
83	Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. <i>Genome Biology</i> , 2015 , 16, 45	18.3	101
82	Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 278-88	6.1	24
81	Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome. <i>Neoplasia</i> , 2015 , 17, 183-9	6.4	27
80	Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. <i>Neuro-Oncology</i> , 2015 , 17, 1356-64	1	76
79	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 1344-55	1	39
78	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015 , 163, 1011-25	56.2	1713
77	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. <i>Cell Systems</i> , 2015 , 1, 197-209	10.6	72

76	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , 2015 , 163, 506-19	56.2	1055
75	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015 , 68, 970-7	10.2	147
74	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
73	Identification of low abundance microbiome in clinical samples using whole genome sequencing. <i>Genome Biology</i> , 2015 , 16, 265	18.3	67
72	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. <i>European Urology</i> , 2015 , 67, 198-201	10.2	105
71	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1334-9	2.2	164
70	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. <i>PLoS ONE</i> , 2015 , 10, e0126633	3.7	27
69	Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2015 , 44-55	1.3	4
68	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3655-3655	5.2	1
67	MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. <i>Cancer Cell</i> , 2014 , 25, 652-652	4.3	206
66	Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. <i>Genome Research</i> , 2014 , 24, 1740-50	9.7	187
65	Comprehensive molecular profiling of lung adenocarcinoma. <i>Nature</i> , 2014 , 511, 543-50	50.4	3310
64	Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 8149-54	11.5	57
63	Integrating biological pathways and genomic profiles with ChiBE 2. <i>BMC Genomics</i> , 2014 , 15, 642	4.5	21
62	Genome-wide analysis of noncoding regulatory mutations in cancer. <i>Nature Genetics</i> , 2014 , 46, 1160-5	36.3	367
61	Collection, integration and analysis of cancer genomic profiles: from data to insight. <i>Current Opinion in Genetics and Development</i> , 2014 , 24, 92-8	4.9	17
60	Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. <i>European Urology</i> , 2014 , 65, 1191-7	10.2	58
59	Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. <i>Bioinformatics</i> , 2014 , 30, 2051-9	7.2	28

58	Copy number alteration burden predicts prostate cancer relapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 11139-44	11.5	218
57	The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2014 , 25, 2372-2378	10.3	26
56	Integrated genomic characterization of papillary thyroid carcinoma. <i>Cell</i> , 2014 , 159, 676-90	56.2	1660
55	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. <i>Nature Genetics</i> , 2014 , 46, 424-6	36.3	231
54	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. <i>Cancer Discovery</i> , 2014 , 4, 1014-21	24.4	98
53	Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. <i>Cancer Research</i> , 2014 , 74, 2340-50	10.1	204
52	Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 1955-64	12.9	173
51	BridgeDb app: unifying identifier mapping services for Cytoscape. <i>F1000Research</i> , 2014 , 3, 148	3.6	8
50	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014 , 5, 8083-92	3.3	46
49	Evaluating cell lines as tumour models by comparison of genomic profiles. <i>Nature Communications</i> , 2013 , 4, 2126	17.4	831
48	Analysis of microRNA-target interactions across diverse cancer types. <i>Nature Structural and Molecular Biology</i> , 2013 , 20, 1325-32	17.6	153
47	The somatic genomic landscape of glioblastoma. <i>Cell</i> , 2013 , 155, 462-77	56.2	2900
46	The molecular diversity of Luminal A breast tumors. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 409-20	4.4	90
45	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3133-40	2.2	226
44	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , 2013 , 45, 1113-20	36.3	3933
43	Emerging landscape of oncogenic signatures across human cancers. <i>Nature Genetics</i> , 2013 , 45, 1127-33	36.3	889
42	Pattern discovery and cancer gene identification in integrated cancer genomic data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 4245-50	11.5	250
41	MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. <i>Journal of Pathology</i> , 2013 , 229, 99-110	9.4	58

40	SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. <i>Cancer Cell</i> , 2013 , 24, 738-50	24.3	111
39	Using MEMo to discover mutual exclusivity modules in cancer. <i>Current Protocols in Bioinformatics</i> , 2013 , Chapter 8, Unit 8.17	24.2	26
38	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013 , 497, 67-73	50.4	2800
37	Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. <i>Science Signaling</i> , 2013 , 6, pl1	8.8	7715
36	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013 , 45, 791-8	36.3	311
35	An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1862-70	9.7	161
34	Comprehensive molecular characterization of clear cell renal cell carcinoma. <i>Nature</i> , 2013 , 499, 43-9	50.4	2184
33	Cancer cells preferentially lose small chromosomes. <i>International Journal of Cancer</i> , 2013 , 132, 2316-26	7.5	98
32	Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. <i>Clinical Cancer Research</i> , 2013 , 19, 3259-67	12.9	233
31	BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 138-46	6.7	47
30	Comprehensive analysis of long non-coding RNAs in ovarian cancer reveals global patterns and targeted DNA amplification. <i>PLoS ONE</i> , 2013 , 8, e80306	3.7	63
29	The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. <i>Cancer Discovery</i> , 2012 , 2, 401-4	24.4	8578
28	53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. <i>Cancer Research</i> , 2012 , 72, 5250-60	10.1	24
27	Comprehensive molecular portraits of human breast tumours. <i>Nature</i> , 2012 , 490, 61-70	50.4	8025
26	MEF promotes stemness in the pathogenesis of gliomas. <i>Cell Stem Cell</i> , 2012 , 11, 836-44	18	27
25	Comprehensive genomic characterization of squamous cell lung cancers. <i>Nature</i> , 2012 , 489, 519-25	50.4	2820
24	Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. <i>PLoS ONE</i> , 2012 , 7, e34546	3.7	94
23	Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. <i>Cancer Research</i> , 2012 , 72, 6142-52	10.1	152

22	Genomic complexity and AKT dependence in serous ovarian cancer. <i>Cancer Discovery</i> , 2012 , 2, 56-67	24.4	89
21	Comparative analysis of SV40 17kT and LT function in vivo demonstrates that LT's C-terminus re-programs hepatic gene expression and is necessary for tumorigenesis in the liver. <i>Oncogenesis</i> , 2012 , 1, e28	6.6	9
20	A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 8212-7	11.5	101
19	Mutual exclusivity analysis identifies oncogenic network modules. <i>Genome Research</i> , 2012 , 22, 398-406	9.7	452
18	Integrative subtype discovery in glioblastoma using iCluster. <i>PLoS ONE</i> , 2012 , 7, e35236	3.7	140
17	Integrated genomic analyses of ovarian carcinoma. <i>Nature</i> , 2011 , 474, 609-15	50.4	5210
16	Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. <i>PLoS ONE</i> , 2011 , 6, e24709	3.7	72
15	Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. <i>Cancer Cell</i> , 2011 , 20, 173-86	24.3	131
14	Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. <i>Cancer Discovery</i> , 2011 , 1, 587-97	24.4	88
13	Off-target effects dominate a large-scale RNAi screen for modulators of the TGF- β pathway and reveal microRNA regulation of TGFBR2. <i>Silence: A Journal of RNA Regulation</i> , 2011 , 2, 3		67
12	¹⁸ F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. <i>Cancer Research</i> , 2011 , 71, 5164-74	10.1	101
11	Pathway Commons, a web resource for biological pathway data. <i>Nucleic Acids Research</i> , 2011 , 39, D685-90	10.1	786
10	Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. <i>Nature Genetics</i> , 2010 , 42, 77-82	36.3	280
9	Automated network analysis identifies core pathways in glioblastoma. <i>PLoS ONE</i> , 2010 , 5, e8918	3.7	268
8	Integrative genomic profiling of human prostate cancer. <i>Cancer Cell</i> , 2010 , 18, 11-22	24.3	2666
7	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 9435-40	11.5	196
6	Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development. <i>International Journal of Cancer</i> , 2005 , 116, 207-17	7.5	20
5	Defining the spermatogonial stem cell. <i>Developmental Biology</i> , 2004 , 269, 393-410	3.1	112

4	Spermatogonial Stem Cells in the Rat and Mouse 2004 , 179-185		1
3	A multitude of genes expressed solely in meiotic or postmeiotic spermatogenic cells offers a myriad of contraceptive targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 12201-6	11.5	463
2	Enabling cross-study analysis of RNA-Sequencing data		4
1	A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants		5